Opinion

Video

Innovations in Small Interfering RNA (siRNA) Therapy

Author(s):

Pam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC

Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.

Related Videos
Understanding Omnipod 5 AID and SECURE-T2D | Image Credit: HCPLive
After the Smoke: Wildfire Cleanup & Air Quality Concerns with Afif El-Hasan, MD
Atopic Disease Hypersensitivity Reactions Vary by Biologic Type with Valerie Jaroenpuntaruk, MD
5 experts in this video
Related Content
Danny Cohn, MD, PhD, Amsterdam UMC, University of Amsterdam
February 25th 2025

Phase 3 Data Supports Sebetralstat Efficacy for HAE Attacks Ahead of PDUFA Date

Victoria Johnson
HCPLive 5 Stories in Under 5: Week of 02/16
February 24th 2025

HCPLive 5 Stories in Under 5: Week of 02/16

HCPLive Editorial Staff
David Salerno, PharmD | Credit: David Salerno on LinkedIn
February 25th 2025

Targeting Delirium May Help Reduce Length of Stay After Liver Transplant

Abigail Brooks, MA
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
February 15th 2025

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Clinical Quiz: Intranasal Corticosteroids in CRSwNP | Image Credit: HCPLive
February 25th 2025

Clinical Quiz: Intranasal Corticosteroids in CRSwNP

HCPLive Editorial Staff
FDA Accepts BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis | Image Credit: US Food and Drug Administration
February 25th 2025

FDA Accepts BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.